Company Overview
About Seismic Therapeutic
Seismic Therapeutic is a clinical-stage biotechnology company based in Boston, Massachusetts that applies machine learning to the discovery and development of novel immunotherapies for autoimmune diseases. Founded with a focus on precision immunology, Seismic built its IMPACT platform to model the complex biology of adaptive immunity — identifying which immune cell populations drive specific autoimmune conditions and designing biologics that precisely modulate those populations without broadly suppressing the immune system. This targeted approach aims to produce safer, more effective treatments for conditions like lupus, rheumatoid arthritis, and inflammatory bowel disease.
Business Model & Competitive Advantage
Seismic raised $121M in a Series B financing in December 2023 and an additional $25M in mid-2025, bringing total capital raised to over $222M. In 2025, the company dosed the first healthy subject in a Phase 1 clinical trial of S-4321, a novel bifunctional antibody designed to modulate dysregulated adaptive immunity across a range of autoimmune diseases. This milestone marks Seismic''s transition from a purely discovery-stage company to one with a clinical-stage asset. Sophie Jones, M.D., joined as Chief Financial Officer in June 2025, supporting the company''s ongoing capital strategy as it advances its pipeline.
Competitive Landscape 2025–2026
Seismic Therapeutic operates at the intersection of ML-driven drug discovery and immunology — a sector that has attracted significant investor and pharma partnership interest given the limited success of blunt immunosuppression therapies in the autoimmune space. The IMPACT platform''s ability to analyze immune cell biology and predict therapeutic interventions computationally represents a meaningful advance over traditional trial-and-error antibody screening, potentially compressing drug discovery timelines and improving first-in-class candidate quality.
Key Differentiators
Emerging Innovator
Seismic Therapeutic is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Similar Brands
Synkrino Biotherapeutics
Synkrino Biotherapeutics is an Oakland, California-based biotechnology company applying artificial intelligence and multiomics analysis to drug discovery in immune-mediated and inflammatory diseases.
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Compare Seismic Therapeutic with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Seismic Therapeutic? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Seismic Therapeutic Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Seismic Therapeutic vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →